Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Prevacid® brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2021
Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2011
Lead Product(s) : Lansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lansoprazole
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Jeil Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2023
Lead Product(s) : Lansoprazole
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Jeil Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin,Avelumab,Lansoprazole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : University of Manchester
Deal Size : Inapplicable
Deal Type : Inapplicable
Aspirin to Be Trialled as Part of New Treatment for Aggressive Form of Breast Cancer
Details : Breast Cancer Now said successful results could lead to further clinical trials of aspirin and avelumab for incurable secondary triple negative breast cancer, which happens when cancer cells that started in the breast spread to other parts of the body.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2021
Lead Product(s) : Aspirin,Avelumab,Lansoprazole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : University of Manchester
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Beijing Xuze Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Study of Lansoprazole Capsules in Healthy Chinese Volunteer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2018
Lead Product(s) : Lansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Beijing Xuze Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Beijing Xuze Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2018
Lead Product(s) : Lansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Beijing Xuze Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardiac Safety of Lansoprazole and Domperidon Combination
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 28, 2017
Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lansoprazole
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : University of Jordan
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of Proton Pump Inhibition on Palpitations
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2017
Lead Product(s) : Lansoprazole
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : University of Jordan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2016
Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
